Dublin, Oct. 10, 2017 -- The "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome.
TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described. A section on drug abuse describes methods of detection of performance-enhancing drugs.
TDM market is analyzed from 2016 to 2026 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2016 to 2026 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 35 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 21 tables, 9 figures and 210 selected references from literature.
Benefits of this report
- Up-to-date one-stop information on therapeutic drug monitoring
- Description of 35 companies involved with their collaborations in this area
- Market analysis 2016-2026
- Market values in major regions
- Strategies for developing markets for therapeutic drug monitoring
- A selected bibliography of 210 publications
- Text is supplemented by 21 tables and 9 figures
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring
- Reference laboratories providing drug monitoring services
- Pharmaceutical companies interested in companion tests for monitoring their drugs
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information about this report visit https://www.researchandmarkets.com/research/hzksfx/therapeutic_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery


Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
OpenAI Addresses Security Vulnerability in macOS App Certification Process
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 



